Re-examining the clinical safety and roles of calcium antagonists in cardiovascular medicine (Q41198027)

28 September 2017

1 reference

title

Re-examining the clinical safety and roles of calcium antagonists in cardiovascular medicine (English)

1 reference

28 September 2017

C R Conti

1

1 reference

28 September 2017

language of work or name

English

0 references

publication date

1 November 1996

1 reference

American Journal of Cardiology

28 September 2017

published in

1 reference

28 September 2017

volume

78

1 reference

28 September 2017

issue

9A

1 reference

28 September 2017

page(s)

13-18

1 reference

The Risk of Myocardial Infarction Associated With Antihypertensive Drug Therapies

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Nifedipine. Dose-related increase in mortality in patients with coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Role of calcium antagonists for heart rate control in atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Frequency-dependent effects of verapamil on atrioventricular nodal conduction in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Frequency-dependent effects of calcium antagonists on atrioventricular conduction and refractoriness: demonstration and characterization in anesthetized dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Frequency-dependent effects of diltiazem on the atrioventricular node during experimental atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Different cardiodepressant potency of various calcium antagonists in human myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Idiopathic recurrent sustained ventricular tachycardia responsive to verapamil: an ECG-electrophysiologic entity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Reversal of left ventricular hypertrophy with isradipine induces diminution of cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Comparison of diltiazem and nifedipine alone and in combination in patients with coronary artery spasm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Increased coronary tone in exertional angina: the beneficial effects of calcium antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Safety of calcium antagonists: dissecting the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Once-daily antihypertensive treatment with calcium antagonists: utopia or reality?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

The effect of diltiazem on mortality and reinfarction after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Unstable and stable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Treatment of unstable angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Nifedipine in unstable angina: a double-blind, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

A randomized study comparing propranolol and diltiazem in the treatment of unstable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Comparison of short-term efficacy of diltiazem and propranolol in unstable angina at rest—A randomized trial in 70 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Use of intravenous diltiazem in patients with acute coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Usefulness of amlodipine for angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Effects of calcium channel blockers on survival after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: the Norwegian Nifedipine Multicenter Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Effect of diltiazem on symptomatic and asymptomatic episodes of ST segment depression occurring during daily life and during exercise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Rationale for the choice of calcium antagonists in chronic stable angina. An objective double-blind placebo-controlled comparison of nifedipine and verapamil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Diltiazem, nifedipine, and their combination in patients with stable angina pectoris: effects on angina, exercise tolerance, and the ambulatory electrocardiographic ST segment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. N-CAP Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Asymptomatic Cardiac Ischemia Pilot (ACIP) study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. The ACIP Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Verapamil suppresses atherosclerosis in cholesterol-fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Mechanism of protection from atherosclerosis by verapamil in the cholesterol-fed rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Suppression of atherosclerosis in cholesterol-fed rabbits by diltiazem injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

New Uses for Calcium Channel Blockers : Therapeutic Implications

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Chronic angiotensin-converting enzyme inhibition may improve sodium excretion in cardiac transplant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Medical treatment of primary pulmonary hypertension: a bridge to transplantation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Primary pulmonary hypertension: beneficial therapy with diltiazem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Sustained beneficial effect of nifedipine in primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Cardioplegic arrest of the myocardium with calcium blocking agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Use of nifedipine in hypertension and Raynaud's phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Controlled trial of nifedipine in the treatment of Raynaud's phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's Phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

Trial of early nifedipine in acute myocardial infarction: the Trent study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900733-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(96)00733-3

1 reference

28 September 2017

1 reference